Three Times Daily Dosing of UT-15C

NCT01746485 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2012-12-12

No results posted yet for this study

Summary

To evaluate the pharmacokinetics of three-times daily dosing of UT-15C in healthy volunteers

Conditions

  • Healthy

Interventions

DRUG

UT-15C

Sponsors & Collaborators

  • United Therapeutics

    lead INDUSTRY

Principal Investigators

  • Theresa Pham, MD · PPD Development, LP

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01746485 on ClinicalTrials.gov